Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Therapeutic effect of novel drug candidate, PRG-N-01, on NF2 syndrome-related tumor

Authors
Chung, Yeon-HoPark, SoyoungLee, MoonyoungLee, JongwonJi, YeongseonSong, Yi JinWoo, Tae-GyunShin, EunbyeolBaek, SongyoungHwang, Young JunKim, YujuKim, MinjuHan, JinKim, Hong-RaeChoi, JungminKim, Bae-HoonPark, Bum-Joon
Issue Date
Dec-2024
Publisher
Duke University Press
Keywords
Merlin; NF2-related schwannomatosis (NF2-SWN); New Drug Candidate; RKIP; TGFβR1
Citation
Neuro-Oncology
Indexed
SCIE
SCOPUS
Journal Title
Neuro-Oncology
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/75768
DOI
10.1093/neuonc/noae282
ISSN
1522-8517
1523-5866
Abstract
BACKGROUND: NF2-related schwannomatosis (NF2-SWN) is associated with multiple benign tumors in the nervous system. NF2-SWN, caused by mutations in the NF2 gene, has developed into intracranial and spinal schwannomas. Because of the high surgical risk and frequent recurrence of multiple tumors, targeted therapy is necessary. However, there are no approved drugs. METHODS: We examined the action mechanism of PRG-N-01, a candidate molecule for NF2-SWN, through the direct binding assay and mass spectrometry. For in vitro anti-proliferative experiments, primary cells derived from NF2 mouse model and patient tumors, were treated with PRG-N-01. The in vivo therapeutic and preventive efficacy was validated via intraperitoneal and oral administration in NF2 mouse model (Postn-Cre; Nf2f/f). Gene expression profile in the DRG of mouse model was explored by RNA sequencing. The pharmacological properties of PRG-N-01 were analyzed through the preclinical study. RESULTS: PRG-N-01 binds to the N-terminal extremity of TGFβR1 (TβR1) kinase domain, where TβR1 and RKIP interact, inhibiting the binding and preventing degradation of RKIP. In vivo administration in the mouse model suppressed schwannoma progression in the DRG. Early oral administration of the PRG-N-01 also demonstrated preventive effects on NF2-SWN. PRG-N-01 treatment suppressed tumor growth genes while upregulating genes related to for normal cell metabolism and schwann cell differentiation in DRG. PRG-N-01 showed druggable properties through the preclinical study including ADME, pharmacodynamics, pharmacokinetics and toxicology. CONCLUSIONS: Together, our study provides the rationale and critical data for a prospective clinical trial of PRG-N-01 in NF2-SWN patients indicating PRG-N-01 as a promising candidate for the treatment. © The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Files in This Item
There are no files associated with this item.
Appears in
Collections
1. Basic Science > Department of Medical Informatics > 1. Journal Articles
3. Graduate School > Graduate School > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Choi, Jungmin photo

Choi, Jungmin
College of Medicine (Department of Medical Informatics)
Read more

Altmetrics

Total Views & Downloads

BROWSE